## MCK: McKesson Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -6.3% below STRENGTH zone (3.0-6.0%); PEG 1.12 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($759.47)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. McKesson (MCK): Revisiting Valuation After a Recent Pullback in a Longer-Term Uptrend**
- Source: Simply Wall Street | 20251206T073827 | Bullish | Relevance: 99%
-  McKesson (MCK) has experienced a recent pullback of about 8% in the past week and 4% over the past month, while still maintaining an 18% gain over three months. Despite this, the stock trades at a notable discount to analyst targets and intrinsic value estimates, suggesting it might be undervalued. The company's strong earnings growth and competitive market position in the pharmaceutical supply chain point to potential buying opportunities, though risks related to drug pricing and industry consolidation exist.

**2. Quantbot Technologies LP Has $1.40 Million Holdings in McKesson Corporation $MCK**
- Source: MarketBeat | 20251208T110544 | Bullish | Relevance: 99%
-  Quantbot Technologies LP significantly reduced its stake in McKesson Corporation, selling 65.2% of its shares but still holding 1,906 shares valued at approximately $1.40 million. McKesson has largely positive Wall Street sentiment with a "Moderate Buy" rating and an average price target of $887.69, following an EPS beat and a 10.2% revenue increase year-over-year. The company recently announced a quarterly dividend of $0.82 per share.

**3. McKesson's (NYSE:MCK) earnings growth rate lags the 37% CAGR delivered to shareholders**
- Source: Yahoo Finance | 20251206T140806 | Somewhat-Bullish | Relevance: 99%
-  McKesson Corporation (NYSE:MCK) has shown impressive share price growth, delivering a 363% return to shareholders over the last five years, equating to a 37% compound annual growth rate (CAGR). However, its earnings per share (EPS) growth during the same period was 20% per year, lagging behind the share price appreciation. This indicates that market sentiment towards McKesson has become more positive, as the share price has grown faster than its underlying earnings.

**4. Baird Financial Group Inc. Has $28.01 Million Stock Holdings in McKesson Corporation $MCK**
- Source: MarketBeat | 20251206T085555 | Bullish | Relevance: 98%
-  Baird Financial Group Inc. increased its stake in McKesson Corporation (NYSE:MCK) by 5.7% during the second quarter, bringing their total holdings to 38,219 shares valued at $28.01 million. Other institutional investors have also adjusted their positions in MCK, which reported strong earnings, beating analyst estimates, and announced a quarterly dividend of $0.82. Analysts have set a consensus price target of $887.69 for McKesson, with an average rating of "Moderate Buy."

**5. California Public Employees Retirement System Sells 96,231 Shares of McKesson Corporation $MCK**
- Source: MarketBeat | 20251207T090817 | Somewhat-Bullish | Relevance: 98%
-  California Public Employees Retirement System (CalPERS) reduced its stake in McKesson Corporation (NYSE:MCK) by 15.8%, selling 96,231 shares but retaining 512,057 shares valued at $375.2 million. This comes as McKesson exceeded quarterly EPS estimates, and analysts have a "Moderate Buy" consensus rating with a target price around $887.69. The company also declared a quarterly dividend of $0.82 per share.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-10 | Wells Fargo | $914 | $816 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-10 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.3%)
- Blackrock Inc.: 9.2% (+0.4%)
- State Street Corpora: 4.7% (+0.9%)
- JPMORGAN CHASE & CO: 4.5% (+16.0%)
- Massachusetts Financ: 3.2% (-1.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.12 suggests fair value with growth premium. Balance sheet: $2.3B free cash flow. Analyst sentiment positive (1 raises, avg +12%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $99.3B |
| Beta | 0.38 |
| 52W Range | $558.13 - $895.58 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.12 |
| Forward P/E | 18.2 |
| Current P/E | 20.6 |
| YoY Growth | 13.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -6.3% (minimal 5-day change). Below STRENGTH zone by 9.3pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). MACD histogram bearish (-10.94), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -6.33% (CS: 3) | Weak |
| RSI_14 | 38.2 | Neutral |
| MACD Histogram | -10.94 | Bearish |
| vs SMA20 | 0.941x | Below |
| vs SMA50 | 0.981x | Below |
| vs SMA200 | 1.102x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $797.93
- **Stop Loss:** $759.47 (4.8% risk)
- **Target:** $836.39 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 13
- **Position Value:** $10,373.09
- **Portfolio %:** 10.37%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-04 (Est: $9.28)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.05 | $9.86 | +8.9% |
| 2025Q2 | $8.15 | $8.26 | +1.4% |
| 2025Q1 | $9.83 | $10.12 | +3.0% |
| 2024Q4 | $7.99 | $8.03 | +0.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*